These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Recent progress in the treatment of hematological malignancies. III. Management of patients with myelodysplastic syndromes and atypical leukemias]. Yoshida Y Nihon Naika Gakkai Zasshi; 1989 Jun; 78(6):785-8. PubMed ID: 2507717 [No Abstract] [Full Text] [Related]
5. Biological molecules in the treatment of hematological disorders. Kurzrock R; Talpaz M; Gutterman U Sangre (Barc); 1989 Feb; 34(1):53-8. PubMed ID: 2469130 [No Abstract] [Full Text] [Related]
6. The use of growth factors in severe aplastic anaemia (SAA). Hinterberger W; Hoffmann S; Bettelheim P; Geissler K; Maurer D; Muhm M Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():129-30. PubMed ID: 2697425 [No Abstract] [Full Text] [Related]
7. Low-dose Ara-C plus granulocyte/macrophage colony-stimulating factor for the treatment of myelodysplastic syndromes. EORTC Leukemia Group. Gerhartz HH; Visani G; Delmer A; Zwierzina H; Ribeiro M; Jacobs A; Marcus R; Baumelou M; Fière D; Labar B Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():36-7. PubMed ID: 2697397 [No Abstract] [Full Text] [Related]
8. The role of bone marrow transplantation in the treatment of myelodysplastic syndromes. Schultz AB; Geller RB; Hillyer CD J Hematother; 1995 Aug; 4(4):323-34. PubMed ID: 7489147 [No Abstract] [Full Text] [Related]
9. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. Ganser A; Hoelzer D Semin Hematol; 1996 Jul; 33(3):186-95. PubMed ID: 8819229 [No Abstract] [Full Text] [Related]
10. [Refractory anemia with partial blastosis. A new therapeutic approach]. Chomienne C; Thomas G; Najean Y; Degos L Presse Med; 1989 Jun; 18(23):1159-63. PubMed ID: 2472631 [TBL] [Abstract][Full Text] [Related]
11. Effect of treatment with rhGM-CSF and low-dose cytosine arabinoside on leukemic blast cells in patients with myelodysplastic syndromes. Hoelzer D; Ganser A; Ottmann OG; Höffken K; Becher R; Lutz D; Krieger O; Diehl V; Lathan B; Boogaerts MA Haematol Blood Transfus; 1990; 33():763-9. PubMed ID: 2182466 [No Abstract] [Full Text] [Related]
12. Phase I/II study with GM-CSF in patients with myelodysplastic syndromes. Hoelzer D; Ganser A; Greher J; Völkers B; Walther F Behring Inst Mitt; 1988 Aug; (83):134-8. PubMed ID: 3071328 [TBL] [Abstract][Full Text] [Related]
16. Effect of GM-CSF on circulating granulocyte-monocyte progenitors in autologous bone marrow transplantation. Nemunaitis J; Appelbaum F; Singer J Lancet; 1989 Dec; 2(8676):1405-6. PubMed ID: 2574358 [No Abstract] [Full Text] [Related]
17. Use of granulocyte-macrophage colony-stimulating factor in patients with malignancy and bone marrow failure. Shadduck RK; Rosenfeld CS; Sulecki M; Phillips N; Przepiorka D; Earle M; Stoller R; Jacobs S Int J Cell Cloning; 1990 Jan; 8 Suppl 1():303-12; discussion 312-3. PubMed ID: 2182742 [TBL] [Abstract][Full Text] [Related]
18. Recurrent spleen enlargement during cyclic granulocyte-macrophage colony-stimulating factor therapy for myelodysplastic syndrome. Delmer A; Karmochkine M; Cadiou M; Gerhartz H; Zittoun R Am J Hematol; 1990 May; 34(1):73-4. PubMed ID: 2183595 [TBL] [Abstract][Full Text] [Related]